Effect of c-MET inhibitor SU11274 upon sensitive (RPMI8226) or multi-resistant (RPMI8226/R5) Multiple Myeloma cell lines

ABSTRACT: The c-MET signaling axis is increasingly implicated in tumorigenesis and chemioresistance. In this study, we investigated gene expression modifications induced by SU11274 (Selleck Chemicals, Boston, USA), a novel selective c-MET inhibitor, in a pair of isogenic multiple myeloma (MM) cell lines either sensitive (RPMI8226) or multi-resistant, highly c-MET expressing (RPMI8226/R5) cells. On the whole, RPMI8226/R5 cells after SU11274 were characterised by wider and diverse gene expression modifications than RPMI8226, indicating that c-MET over-expression, and its inhibition, is an important aspect of the adaptive response associated to drug resistance. RPMI8226 and RPMI8226/R5 cells are cultured in RPMI 1640 supplemented with10% fetal calf serum (FCS), 100U/ml penicillin and streptomicin (Eur

ORGANISM(S): Homo sapiens

SUBMITTER: angelina boccarelli 

PROVIDER: E-GEOD-38204 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress